Trial Profile
PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms LNH09-7B
Most Recent Events
- 12 Dec 2023 Results comparing Synthetic control arms (SCA) with real-world (RW) data treated by anti-CD20+miniCHOP in LNH03-7B and LNH09-7B along with SENIOR trial, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 06 Dec 2016 Results of pooled analysis assessing CNS relapse, risk factors and specific survival in very elderly DLBCL patients using patient data from this and NCT01087424 trial, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 07 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.